Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse LEUKEMIA Sidana, S., Tandon, N., Dispenzieri, A., Gertz, M. A., Buadi, F. K., Lacy, M. Q., Dingli, D., Fonder, A. L., Hayman, S. R., Hobbs, M. A., Gonsalves, W. I., Warsame, R. M., Kourelis, T., Hwa, Y., Kapoor, P., Kyle, R. A., Leung, N., Go, R. S., Rajkumar, S., Kumar, S. K. 2019; 33 (3): 730–38

Abstract

Achieving a complete response (CR) is associated with improved overall survival (OS) in multiple myeloma (MM), but data on duration of CR (DurCR) are limited. We evaluated 351 patients (2004-2016), achieving CR with first-line therapy. Patients with sustained DurCR?=?24 months (n?=?177) had better OS; 150 vs. 81 months, p?

View details for DOI 10.1038/s41375-018-0271-1

View details for Web of Science ID 000460406600015

View details for PubMedID 30323358